查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2157170

AAV基因治療注射劑市場：全球市場預測，2026-2032年

AAV Gene Therapy Injection Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，AAV 基因治療注射劑市場將成長至 204.5 億美元，複合年成長率為 21.66%。

主要市場統計數據
基準年 2025 51.8億美元
預計年份：2026年 62.7億美元
預測年份 2032 204.5億美元
複合年成長率 (%) 21.66%

AAV基因治療注射：執行摘要

腺結合病毒（AAV）基因治療注射療法利用腺相關病毒載體將遺傳物質送至目標細胞。分子設計、生產製造、臨床開發、監管科學以​​及長期患者監測等方面的進步推動了該領域的發展。取得進展需要證明其療效的持續性，同時控制免疫反應，克服載體生產的複雜性，確保患者能夠獲得治療，並履行安全義務。

從實驗平台到綜合治療系統

該領域的發展趨勢正從孤立的產品開發轉向涵蓋載體工程、衣殼選擇、療效測試、製程控制、冷鏈物流和專業臨床給藥的綜合能力。研發人員更重視病患分層、終點選擇、持久性評估和標準化比較方法。生產製造仍然是一個核心限制因素，因為生產品質、批間阻礙因素、可擴展性和分析表徵直接影響臨床可靠性和法規核准。

人工智慧能夠促進藥物的發現、開發和應用。

人工智慧可以透過識別衣殼結構、組織親和性、有效載荷設計和免疫識別之間的關係來支持腺相關病毒（AAV）的研究。在研發階段，機器學習工具可以輔助生物標記選擇、病患辨識、臨床實驗規劃、影像和不利事件訊號檢測。在生產製造階段，數據驅動的監控可以識別製程偏差並改善分析工作流程。這些應用需要檢驗的資料集、可解釋的模型、隱私控制和人工監督。人工智慧不能取代實驗驗證或監管課責。

AAV基因治療發展的區域趨勢

北美擁有先進的生物技術基礎設施、專業的臨床中心以及經驗豐富的監管和生產網路。歐洲受益於強大的學術合作和科學研究能力，歐盟也持續優先推動監管和品質要求的協調統一。亞太地區的轉化研究、生產能力和臨床專業知識正在擴展，日本、中國、韓國、印度和澳洲各自貢獻獨特的優勢。拉丁美洲的專業治療和研究能力正在發展，但醫療服務的可及性、保險報銷和物流仍然是關鍵的考慮因素。中東地區先進的醫療基礎設施和精準醫療投資正在穩步推進，而非洲在專業醫療服務、診斷、資金籌措和供應鏈連續性方面面臨更廣泛的限制。各地區的進展都取決於當地的人力資源發展、永續的資源取得以及跨境證據的累積。

東協、金磚國家、歐盟、七國集團、海灣合作理事會和北約對生態系統的影響

東南亞國協可以透過共用監管知識、建立區域轉診管道和協調專家培訓而獲益。金磚國家擁有多元化的研究、製造和醫療保健體系，這不僅創造了合作機遇，也要求在品質和臨床標準方面進行精心協調。歐盟支持跨境科學和監管協調。七國集團成員國在研究、醫療保健和政策方面擁有雄厚實力，同時也面臨成本效益和長期治療效果的挑戰。海灣合作理事會成員國正在加強其先進的醫療保健基礎設施，並有潛力成為區域治療中心。北約成員國共同構成了一個成熟的生物醫學生態系統和多元化的國家體系。在衛生安全、供應鏈韌性和科學準備方面的合作可以在不取代私人監管流程的前提下，保障醫療服務的連續性。

國家觀點的研究、製造與取得途徑

美國在載體科學、臨床開發、生產製造和監管實踐方面擁有雄厚的實力。加拿大在學術研究、專業醫療保健和公共部門領域具備強大的科學研究能力。英國、法國、德國、義大利和西班牙受益於成熟的生物醫學機構和歐洲內部的合作，特別注重醫療技術評估和公平取得。中國正在加強國內的研究、生產製造和臨床基礎設施建設，而日本在再生醫學領域擁有先進的專業知識和完善的法規環境。韓國正在推動生物技術和生產製造能力的提升。澳洲將強大的臨床研究能力與地域分散的醫療保健服務體系結合。印度正在拓展其生物技術、臨床和生產製造能力，而巴西和墨西哥則致力於建構區域性專業技術，同時兼顧醫療資源取得和基礎設施的挑戰。俄羅斯保持其科學研究和醫療保健能力，但國際合作、供應連續性和監管互通性正在影響其發展狀況。

領導者建構永續AAV專案的優先事項

產業領導者應從設計初期就優先考慮可製造性和分析控制，包括可擴展的製程流程、可靠的療效檢測法和清晰的可比較策略。臨床項目應納入免疫分析、有意義且持久的終點指標、長期追蹤以及透明的風險溝通。與專業治療中心建立合作關係可以最佳化給藥方案、患者選擇和治療後監測。領導者也應建立穩健的供應鏈網路，儘早與監管機構和保險公司展開對話，並設計符合實際療效和可負擔性的證據包。負責任的人工智慧管治應包括模型檢驗、可審計性、網路安全以及對人類決策的明確問責。

數據驅動的管理績效評估調查方法

本執行摘要整合了載體科學、臨床開發、生產製造、監管、醫療服務、區域能力和技術應用等方面的成熟行業主題，並基於AAV基因治療注射劑市場的特定範圍進行闡述。地理範圍與所要求的區域、群體和國家一致。說明為定性描述，僅限於已廣泛記錄的結構性條件。本報告不包含市場規模估算和預測、市場佔有率、預測或公司特定評估。解讀本報告應結合最新的監管文件、同行評審研究、臨床試驗記錄、生產指南以及國家級醫療保健系統相關證據。

結論：執行品質將決定AAV的發展過程。

AAV基因療法的研發正處於一個高度跨學科的環境中，除了科學潛力之外，生產可靠性、臨床持久性、安全性監測和實際可及性也至關重要。鑑於區域和國家能力的差異，合作、人力資源發展、彈性供應鏈和實證政策至關重要。最佳方案將整合負責任的創新、嚴格的品管系統和以患者為中心的醫療服務，從而推動該領域的發展，同時維護臨床醫生、監管機構、患者和醫療系統之間的信任。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 AAV基因治療注射劑市場：依適應症分類

  • 血友病
  • 遺傳性視網膜疾病
  • 溶小體儲積症
    • 法布瑞氏症
    • 高雪氏症
    • 龐貝氏症
  • 神經病變
    • 帕金森氏症
    • 脊髓性肌肉萎縮症

第8章：AAV基因治療注射劑市場：依載體類型分類

  • AAV2
  • AAV5
  • AAV8
  • AAV9

第9章：AAV基因治療注射劑市場：依給藥途徑分類

  • 肌肉內部
  • 鞘內腔
  • 靜脈

第10章：AAV基因治療注射劑市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第11章 AAV基因治療注射市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第12章 AAV基因治療注射市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 AAV基因治療注射市場：按國家/地區分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章 競爭格局

  • 2025年市佔率分析
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第15章：公司簡介

  • Abeona Therapeutics Inc.
  • Adverum Biotechnologies Inc.
  • Astellas Pharma Inc.
  • Biogen Inc.
  • BioMarin Pharmaceutical Inc.
  • bluebird bio Inc.
  • Capsida Biotherapeutics
  • CRISPR Therapeutics AG
  • CSL Behring LLC
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • Krystal Biotech Inc.
  • MeiraGTx Holdings PLC
  • Novartis AG
  • Pfizer Inc.
  • PTC Therapeutics
  • REGENXBIO Inc.
  • Rocket Pharmaceuticals Inc.
  • Sangamo Therapeutics Inc.
  • Sarepta Therapeutics Inc.
  • Spark Therapeutics Inc.
  • Takeda Pharmaceutical Company Limited
  • uniQure NV
  • Voyager Therapeutics Inc.

第16章 主要專家

Product Code: MRR-EF0BD2D829C4

The AAV Gene Therapy Injection Market is projected to grow by USD 20.45 billion at a CAGR of 21.66% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.18 billion
Estimated Year [2026] USD 6.27 billion
Forecast Year [2032] USD 20.45 billion
CAGR (%) 21.66%

AAV Gene Therapy Injection: Executive Summary

AAV gene therapy injections use adeno-associated virus vectors to deliver genetic payloads to target cells. The field is shaped by advances in molecular design, manufacturing, clinical development, regulatory science, and long-term patient monitoring. Progress depends on demonstrating durable benefit while managing immune responses, vector production complexity, treatment access, and safety obligations.

From Experimental Platforms to Integrated Therapeutic Systems

The landscape is shifting from isolated product development toward integrated capabilities spanning vector engineering, capsid selection, potency testing, process control, cold-chain logistics, and specialized clinical administration. Developers are placing greater emphasis on patient stratification, endpoint selection, durability assessment, and standardized comparability methods. Manufacturing remains a central constraint because production quality, batch consistency, scalability, and analytical characterization directly influence clinical confidence and regulatory review.

Artificial Intelligence Strengthens Discovery, Development, and Operations

Artificial intelligence can support AAV research by identifying relationships among capsid structure, tissue tropism, payload design, and immune recognition. In development, machine-learning tools may assist biomarker selection, patient identification, trial-site planning, imaging interpretation, and adverse-event signal detection. In manufacturing, data-driven monitoring can help identify process deviations and improve analytical workflows. These applications require validated datasets, explainable models, privacy controls, and human oversight; AI does not replace experimental confirmation or regulatory accountability.

Regional Dynamics Across AAV Gene Therapy Development

North America combines advanced biotechnology infrastructure, specialized clinical centers, and experienced regulatory and manufacturing networks. Europe benefits from strong academic collaboration and coordinated scientific capabilities, while the European Union continues to emphasize harmonized regulatory and quality expectations. Asia-Pacific is expanding translational research, manufacturing capacity, and clinical expertise, with Japan, China, South Korea, India, and Australia contributing distinct capabilities. Latin America is developing specialist treatment and research capacity, although access, reimbursement, and logistics remain important considerations. The Middle East is investing in advanced healthcare infrastructure and precision medicine, while Africa faces wider constraints in specialist services, diagnostics, financing, and supply-chain continuity. Regional progress will depend on local training, sustainable procurement, and cross-border evidence generation.

How ASEAN, BRICS, EU, G7, GCC, and NATO Shape the Ecosystem

ASEAN countries can benefit from shared regulatory learning, regional referral pathways, and coordinated specialist training. BRICS members bring diverse research, manufacturing, and healthcare systems, creating opportunities for collaboration while requiring careful alignment of quality and clinical standards. The European Union supports cross-border scientific and regulatory coordination. G7 members contribute substantial research, healthcare, and policy capacity, while also confronting affordability and long-term outcome challenges. GCC states are strengthening advanced-care infrastructure and may serve as regional treatment hubs. NATO members, considered collectively, span mature biomedical ecosystems and diverse national systems; cooperation in health security, supply resilience, and scientific preparedness can support continuity without substituting for civilian regulatory processes.

Country Perspectives on Research, Manufacturing, and Access

The United States has deep capabilities in vector science, clinical development, manufacturing, and regulatory practice. Canada contributes academic research, specialized healthcare, and public-sector scientific capacity. The United Kingdom, France, Germany, Italy, and Spain benefit from established biomedical institutions and European collaboration, with particular attention to health-technology assessment and equitable access. China is strengthening domestic research, manufacturing, and clinical infrastructure, while Japan has advanced regenerative-medicine expertise and a structured regulatory environment. South Korea is developing biotechnology and manufacturing capabilities. Australia combines strong clinical research with geographically dispersed care delivery. India is expanding biotechnology, clinical, and manufacturing capacity, while Brazil and Mexico are building regional expertise amid access and infrastructure considerations. Russia maintains scientific and healthcare capabilities, though international collaboration, supply continuity, and regulatory interoperability affect development conditions.

Priorities for Leaders Building Sustainable AAV Programs

Industry leaders should prioritize manufacturability and analytical control from the earliest design stage, including scalable processes, robust potency assays, and clear comparability strategies. Clinical programs should incorporate immune profiling, meaningful durability endpoints, long-term follow-up, and transparent risk communication. Partnerships with specialist treatment centers can strengthen administration, patient selection, and post-treatment monitoring. Leaders should also establish resilient supply networks, engage regulators and payers early, and design evidence packages that address real-world outcomes and affordability. Responsible AI governance should include model validation, auditability, cybersecurity, and explicit human decision ownership.

Methodology for a Data-Grounded Executive Assessment

This executive summary uses the specified AAV gene therapy injection market scope and synthesizes established industry themes across vector science, clinical development, manufacturing, regulation, healthcare delivery, regional capacity, and technology adoption. Geographic coverage follows the requested regions, groups, and countries. Claims are qualitative and limited to broadly documented structural conditions; no market estimates, market shares, forecasts, or company-specific assessments are included. Interpretation should be supplemented with current regulatory documents, peer-reviewed studies, clinical-trial records, manufacturing guidance, and country-level health-system evidence.

Conclusion: Execution Quality Will Determine AAV Progress

AAV gene therapy injections are advancing within a highly interdisciplinary environment where scientific promise must be matched by manufacturing reliability, clinical durability, safety monitoring, and practical access. Regional and country capabilities are uneven, making collaboration, workforce development, resilient supply chains, and evidence-based policy important. The strongest programs will integrate responsible innovation with rigorous quality systems and patient-centered delivery, allowing the field to progress while maintaining confidence among clinicians, regulators, patients, and healthcare systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. AAV Gene Therapy Injection Market, by Indication

  • 7.1. Introduction
  • 7.2. Hemophilia
  • 7.3. Inherited Retinal Disease
  • 7.4. Lysosomal Storage Disorders
    • 7.4.1. Fabry Disease
    • 7.4.2. Gaucher Disease
    • 7.4.3. Pompe Disease
  • 7.5. Neurological Disorders
    • 7.5.1. Parkinson's Disease
    • 7.5.2. Spinal Muscular Atrophy

8. AAV Gene Therapy Injection Market, by Vector Type

  • 8.1. Introduction
  • 8.2. AAV2
  • 8.3. AAV5
  • 8.4. AAV8
  • 8.5. AAV9

9. AAV Gene Therapy Injection Market, by Delivery Method

  • 9.1. Introduction
  • 9.2. Intramuscular
  • 9.3. Intrathecal
  • 9.4. Intravenous

10. AAV Gene Therapy Injection Market, by End User

  • 10.1. Introduction
  • 10.2. Hospitals
  • 10.3. Research Institutes
  • 10.4. Specialty Clinics

11. AAV Gene Therapy Injection Market, by Region

  • 11.1. Introduction
  • 11.2. Asia-Pacific
  • 11.3. North America
  • 11.4. Latin America
  • 11.5. Europe
  • 11.6. Middle East
  • 11.7. Africa

12. AAV Gene Therapy Injection Market, by Group

  • 12.1. Introduction
  • 12.2. ASEAN
  • 12.3. GCC
  • 12.4. European Union
  • 12.5. BRICS
  • 12.6. G7
  • 12.7. NATO

13. AAV Gene Therapy Injection Market, by Country

  • 13.1. Introduction
  • 13.2. United States
  • 13.3. Canada
  • 13.4. Mexico
  • 13.5. Brazil
  • 13.6. United Kingdom
  • 13.7. Germany
  • 13.8. France
  • 13.9. Russia
  • 13.10. Italy
  • 13.11. Spain
  • 13.12. China
  • 13.13. India
  • 13.14. Japan
  • 13.15. Australia
  • 13.16. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2025
  • 14.2. Market Concentration Analysis, 2025
    • 14.2.1. Concentration Ratio (CR)
    • 14.2.2. Herfindahl Hirschman Index (HHI)
  • 14.3. Recent Developments & Impact Analysis, 2025
  • 14.4. Product Portfolio Analysis, 2025
  • 14.5. Benchmarking Analysis, 2025

15. Company Profiles

  • 15.1. Abeona Therapeutics Inc.
  • 15.2. Adverum Biotechnologies Inc.
  • 15.3. Astellas Pharma Inc.
  • 15.4. Biogen Inc.
  • 15.5. BioMarin Pharmaceutical Inc.
  • 15.6. bluebird bio Inc.
  • 15.7. Capsida Biotherapeutics
  • 15.8. CRISPR Therapeutics AG
  • 15.9. CSL Behring LLC
  • 15.10. F. Hoffmann-La Roche Ltd.
  • 15.11. Gilead Sciences Inc.
  • 15.12. Krystal Biotech Inc.
  • 15.13. MeiraGTx Holdings PLC
  • 15.14. Novartis AG
  • 15.15. Pfizer Inc.
  • 15.16. PTC Therapeutics
  • 15.17. REGENXBIO Inc.
  • 15.18. Rocket Pharmaceuticals Inc.
  • 15.19. Sangamo Therapeutics Inc.
  • 15.20. Sarepta Therapeutics Inc.
  • 15.21. Spark Therapeutics Inc.
  • 15.22. Takeda Pharmaceutical Company Limited
  • 15.23. uniQure N.V.
  • 15.24. Voyager Therapeutics Inc.

16. Key Experts

LIST OF FIGURES

  • FIGURE 1. Global AAV Gene Therapy Injection Market, Years Considered for the Study
  • FIGURE 2. Global AAV Gene Therapy Injection Market, Research Design
  • FIGURE 3. Global AAV Gene Therapy Injection Market, Research Framework
  • FIGURE 4. Global AAV Gene Therapy Injection Market, Data Triangulation
  • FIGURE 5. Global AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global AAV Gene Therapy Injection Market Size, by Indication, 2025 vs 2032 (%)
  • FIGURE 7. Global AAV Gene Therapy Injection Market Size, by Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global AAV Gene Therapy Injection Market Size, by Vector Type, 2025 vs 2032 (%)
  • FIGURE 9. Global AAV Gene Therapy Injection Market Size, by Vector Type, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global AAV Gene Therapy Injection Market Size, by Delivery Method, 2025 vs 2032 (%)
  • FIGURE 11. Global AAV Gene Therapy Injection Market Size, by Delivery Method, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global AAV Gene Therapy Injection Market Size, by End User, 2025 vs 2032 (%)
  • FIGURE 13. Global AAV Gene Therapy Injection Market Size, by End User, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global AAV Gene Therapy Injection Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 15. Global AAV Gene Therapy Injection Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global AAV Gene Therapy Injection Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 17. Global AAV Gene Therapy Injection Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 18. Global AAV Gene Therapy Injection Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 19. Global AAV Gene Therapy Injection Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global AAV Gene Therapy Injection Market Segmentation & Coverage
  • TABLE 2. Global AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 4. Global Hemophilia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Hemophilia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Hemophilia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Inherited Retinal Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Inherited Retinal Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Inherited Retinal Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Lysosomal Storage Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Lysosomal Storage Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Lysosomal Storage Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Fabry Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Fabry Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Fabry Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Gaucher Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Gaucher Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Gaucher Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Pompe Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Pompe Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Pompe Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Neurological Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Neurological Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Neurological Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Parkinson's Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Parkinson's Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Parkinson's Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Spinal Muscular Atrophy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Spinal Muscular Atrophy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Spinal Muscular Atrophy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 32. Global AAV2 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 33. Global AAV2 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 34. Global AAV2 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 35. Global AAV5 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 36. Global AAV5 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 37. Global AAV5 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 38. Global AAV8 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 39. Global AAV8 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 40. Global AAV8 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 41. Global AAV9 Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 42. Global AAV9 Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 43. Global AAV9 Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 44. Global AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 45. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 46. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 47. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 48. Global Intrathecal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 49. Global Intrathecal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 50. Global Intrathecal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 51. Global Intravenous Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 52. Global Intravenous Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 53. Global Intravenous Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 54. Global AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 55. Global Hospitals Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 56. Global Hospitals Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 57. Global Hospitals Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 58. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 59. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 60. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 61. Global Specialty Clinics Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 62. Global Specialty Clinics Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 63. Global Specialty Clinics Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 64. Global AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 65. Asia-Pacific AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Asia-Pacific AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 67. Asia-Pacific AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 68. Asia-Pacific AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 69. Asia-Pacific AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 70. Asia-Pacific AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 71. Asia-Pacific AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 72. North America AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. North America AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 74. North America AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 75. North America AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 76. North America AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 77. North America AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 78. North America AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 79. Latin America AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 80. Latin America AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 81. Latin America AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 82. Latin America AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 83. Latin America AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 84. Latin America AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 85. Latin America AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 86. Europe AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 87. Europe AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 88. Europe AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 89. Europe AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 90. Europe AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 91. Europe AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 92. Europe AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 93. Middle East AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 94. Middle East AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 95. Middle East AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 96. Middle East AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 97. Middle East AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 98. Middle East AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 99. Middle East AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 100. Africa AAV Gene Therapy Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 101. Africa AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 102. Africa AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 103. Africa AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 104. Africa AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 105. Africa AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 106. Africa AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 107. Global AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 108. ASEAN AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. ASEAN AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 110. ASEAN AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 111. ASEAN AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 112. ASEAN AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 113. ASEAN AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 114. ASEAN AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 115. GCC AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. GCC AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 117. GCC AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 118. GCC AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 119. GCC AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 120. GCC AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 121. GCC AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 122. European Union AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 123. European Union AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 124. European Union AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 125. European Union AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 126. European Union AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 127. European Union AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 128. European Union AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 129. BRICS AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 130. BRICS AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 131. BRICS AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 132. BRICS AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 133. BRICS AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 134. BRICS AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 135. BRICS AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 136. G7 AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 137. G7 AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 138. G7 AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 139. G7 AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 140. G7 AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 141. G7 AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 142. G7 AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 143. NATO AAV Gene Therapy Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 144. NATO AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 145. NATO AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 146. NATO AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 147. NATO AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 148. NATO AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 149. NATO AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 150. Global AAV Gene Therapy Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 151. United States AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 152. United States AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 153. United States AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 154. United States AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 155. United States AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 156. United States AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 157. United States AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 158. Canada AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 159. Canada AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 160. Canada AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 161. Canada AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 162. Canada AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 163. Canada AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 164. Canada AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 165. Mexico AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 166. Mexico AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 167. Mexico AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 168. Mexico AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 169. Mexico AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 170. Mexico AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 171. Mexico AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 172. Brazil AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 173. Brazil AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 174. Brazil AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 175. Brazil AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 176. Brazil AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 177. Brazil AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 178. Brazil AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 179. United Kingdom AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 180. United Kingdom AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 181. United Kingdom AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 182. United Kingdom AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 183. United Kingdom AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 184. United Kingdom AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 185. United Kingdom AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 186. Germany AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 187. Germany AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 188. Germany AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 189. Germany AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 190. Germany AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 191. Germany AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 192. Germany AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 193. France AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 194. France AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 195. France AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 196. France AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 197. France AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 198. France AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 199. France AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 200. Russia AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 201. Russia AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 202. Russia AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 203. Russia AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 204. Russia AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 205. Russia AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 206. Russia AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 207. Italy AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 208. Italy AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 209. Italy AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 210. Italy AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 211. Italy AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 212. Italy AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 213. Italy AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 214. Spain AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 215. Spain AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 216. Spain AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 217. Spain AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 218. Spain AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 219. Spain AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 220. Spain AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 221. China AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 222. China AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 223. China AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 224. China AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 225. China AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 226. China AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 227. China AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 228. India AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 229. India AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 230. India AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 231. India AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 232. India AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 233. India AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 234. India AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 235. Japan AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 236. Japan AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 237. Japan AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 238. Japan AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 239. Japan AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 240. Japan AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 241. Japan AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 242. Australia AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 243. Australia AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 244. Australia AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 245. Australia AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 246. Australia AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 247. Australia AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 248. Australia AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 249. South Korea AAV Gene Therapy Injection Market Size, 2017-2032 (USD Million)
  • TABLE 250. South Korea AAV Gene Therapy Injection Market Size, by Indication, 2017-2032 (USD Million)
  • TABLE 251. South Korea AAV Gene Therapy Injection Market Size, by Lysosomal Storage Disorders, 2017-2032 (USD Million)
  • TABLE 252. South Korea AAV Gene Therapy Injection Market Size, by Neurological Disorders, 2017-2032 (USD Million)
  • TABLE 253. South Korea AAV Gene Therapy Injection Market Size, by Vector Type, 2017-2032 (USD Million)
  • TABLE 254. South Korea AAV Gene Therapy Injection Market Size, by Delivery Method, 2017-2032 (USD Million)
  • TABLE 255. South Korea AAV Gene Therapy Injection Market Size, by End User, 2017-2032 (USD Million)
  • TABLE 256. Global AAV Gene Therapy Injection Market Share, by Key Player, 2025
  • TABLE 257. Global AAV Gene Therapy Injection Market, Key Experts